Regina Selb

Regina Selb

Auto-generated profile, based on publicly available information

Regina Selb

Unit 'HIV/AIDS, STI and Blood-borne Infections', Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2019 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
VSValerie Stock
Valerie Stock
LBLinda Böhmert
Linda Böhmert
ELElisa Lisicki
Elisa Lisicki
RBRafael Block
Rafael Block
JCJulia Cara-Carmona
Julia Cara-Carmona
ALAlfonso Lampen
Alfonso Lampen

1 January 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RSRegina Selb
Regina Selb
JEJulia Eckl-Dorna
Julia Eckl-Dorna
ANAlina Neunkirchner
Alina Neunkirchner
KSKlaus Schmetterer
Klaus Schmetterer
KMKatharina Marth
Katharina Marth
VNVerena Niederberger
Verena Niederberger

7 July 2022 in Eurosurveillance
Verified
Journal Article
Open access
RSRegina Selb
Regina Selb
DWDirk Werber
Dirk Werber
GFGerhard Falkenhorst
Gerhard Falkenhorst
GSGyde Steffen
Gyde Steffen
RLRaskit Lachmann
Raskit Lachmann
OGon behalf of the Berlin MPX study group
on behalf of the Berlin MPX study group
By 22 June 2022, 521 cases of monkeypox were notified in Germany. The median age was 38 years (IQR: 32–44); all cases were men. In Berlin, where 69% of all cases occurred, almost all were men who have sex with men. Monkeypox virus likely circulated unrecognised in Berlin before early May. Since mid-May, we observed a shift from travel-associated infections to mainly autochthonous transmission that predominantly took place in Berlin, often in association with visits to clubs and parties.

1 September 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
EWEva Wollmann
Eva Wollmann
CLChristian Lupinek
Christian Lupinek
MKMichael Kundi
Michael Kundi
RSRegina Selb
Regina Selb
VNVerena Niederberger
Verena Niederberger
RVRudolf Valenta
Rudolf Valenta

1 March 2017 in Food and Chemical Toxicology
Verified
Journal Article
Open access
RSR. Selb
R. Selb
JWJ.M. Wal
J.M. Wal
FMF. Javier Moreno
F. Javier Moreno
MLM. Lovik
M. Lovik
CMC. Mills
C. Mills
AFA. Fernandez
A. Fernandez
According to EU regulation, genetically modified (GM) plants considered to be allergenic have to be assessed concerning their endogenous allergens before placement on the EU market, in line with the international standards described in Codex Alimentarius. Under such premises, a quantitative relevant increase in allergens might occur in GM plants as an unintended effect compared with conventionally produced crops, which could pose a risk to consumers. Currently, data showing a connection between dose and allergic sensitisation are scarce since the pathophysiological mechanisms of sensitisation are insufficiently understood. In contrast, data on population dose-distribution relationships acquired by oral food challenge are available showing a connection between quantity of allergenic protein consumed and the population of allergic individuals experiencing reactions. Soybean is currently the only recognised allergenic GM food by law for which EFSA has received applications and was therefore taken as an example for defining an assessment strategy. Identification of potential allergens, methodology for quantification as well as risk assessment considerations, are discussed. A strategy is proposed for the identification, assessment and evaluation of potential hazards/risks concerning endogenous allergenicity in food derived from plants developed by biotechnology. This approach could be expanded to other allergenic foods in the future, whenever required.

26 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EWEva E. Waltl
Eva E. Waltl
RSRegina Selb
Regina Selb
JEJulia Eckl-Dorna
Julia Eckl-Dorna
CMChristian A. Mueller
Christian A. Mueller
CCClarissa R. Cabauatan
Clarissa R. Cabauatan
VNVerena Niederberger
Verena Niederberger
The respiratory epithelium is a barrier against pathogens and allergens and a target for therapy in respiratory allergy, asthma and chronic obstructive pulmonary disease (COPD). We investigated barrier-damaging factors and protective factors by real-time measurement of respiratory cell barrier integrity. Barrier integrity to cigarette smoke extract (CSE), house dust mite (HDM) extract, interferon-γ (IFN-γ) or human rhinovirus (HRV) infection alone or in combination was assessed. Corticosteroids, lipopolysaccharide (LPS), and nasal mucus proteins were tested for their ability to prevent loss of barrier integrity. Real-time impedance-based measurement revealed different patterns of CSE-, HDM-, IFN-γ- and HRV-induced damage. When per se non-damaging concentrations of harmful factors were combined, a synergetic effect was observed only for CSE and HDM. Betamethasone prevented the damaging effect of HRV and CSE, but not damage caused by HDM or IFN-γ. Real-time impedance-based measurement of respiratory epithelial barrier function is useful to study factors, which are harmful or protective. The identification of a synergetic damaging effect of CSE and HDM as well as the finding that Betamethasone protects against HRV- and CSE-induced damage may be important for asthma and COPD.